Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection
Abstract Background The SARS-CoV-2 virus is the causing agent of the Coronavirus disease 2019 (COVID-19) characterized by a huge pro-inflammatory response and coagulation disorders that may lead to for its severe forms, in organ failure or even death. As major players of thrombo-inflammation, platel...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Virology Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12985-021-01680-3 |
| _version_ | 1831569091306979328 |
|---|---|
| author | Hind Hamzeh-Cognasse Alexandre Mansour Florian Reizine Patrick Mismetti Isabelle Gouin-Thibault Fabrice Cognasse |
| author_facet | Hind Hamzeh-Cognasse Alexandre Mansour Florian Reizine Patrick Mismetti Isabelle Gouin-Thibault Fabrice Cognasse |
| author_sort | Hind Hamzeh-Cognasse |
| collection | DOAJ |
| description | Abstract Background The SARS-CoV-2 virus is the causing agent of the Coronavirus disease 2019 (COVID-19) characterized by a huge pro-inflammatory response and coagulation disorders that may lead to for its severe forms, in organ failure or even death. As major players of thrombo-inflammation, platelets release large amounts of immunomodulatory molecules and regulate leukocyte and endothelial activity, which are both altered in COVID-19. Altogether, this makes platelets a very likely actor of the thrombo-inflammatory complications of COVID-19. Thus, we propose to identify a platelet inflammatory signature of severe COVID-19 specifically modulated throughout the course of the disease. Methods Luminex technology and enzyme-linked immunosorbent assay were used to assess plasma levels of platelet inflammatory markers in patients with severe acute respiratory syndrome coronavirus 2 infection on admission and for 14 days afterwards. Results In accordance with the observations of other teams, we evidence that the plasma levels of the platelet soluble (s)CD40L is significantly elevated in the early stages of the disease. Interestingly we observe that the plasma level of sCD40L decreases overtime while that of sCD62P increases significantly. Conclusions Our data suggest that there is a platelet signature of inflammatory response to SARS-COv-2 infection which varies overtime and could serve as monitoring biomarkers of patient inflammatory state. Clinical trial registration number: 2020-A01100-39; title: Human Ab Response & immunoMONItoring of COVID-19 Patients, registration date: 05/25/2020; URL of the registry: https://clinicaltrials.gov/ct2/history/NCT04373200?V_5=View . |
| first_indexed | 2024-12-17T12:26:17Z |
| format | Article |
| id | doaj.art-274401671ed34819904806ac4733d690 |
| institution | Directory Open Access Journal |
| issn | 1743-422X |
| language | English |
| last_indexed | 2024-12-17T12:26:17Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Virology Journal |
| spelling | doaj.art-274401671ed34819904806ac4733d6902022-12-21T21:48:45ZengBMCVirology Journal1743-422X2021-10-011811410.1186/s12985-021-01680-3Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infectionHind Hamzeh-Cognasse0Alexandre Mansour1Florian Reizine2Patrick Mismetti3Isabelle Gouin-Thibault4Fabrice Cognasse5INSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-MonnetDepartment of Anesthesiology Critical Care Medicine and Perioperative Medicine, CHU de RennesIntensive Care Unit, CHU de RennesINSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-MonnetINSERM, CIC 1414, Université de Rennes, CHU de RennesINSERM, U1059, SAINBIOSE, Université de Lyon, Université Jean-MonnetAbstract Background The SARS-CoV-2 virus is the causing agent of the Coronavirus disease 2019 (COVID-19) characterized by a huge pro-inflammatory response and coagulation disorders that may lead to for its severe forms, in organ failure or even death. As major players of thrombo-inflammation, platelets release large amounts of immunomodulatory molecules and regulate leukocyte and endothelial activity, which are both altered in COVID-19. Altogether, this makes platelets a very likely actor of the thrombo-inflammatory complications of COVID-19. Thus, we propose to identify a platelet inflammatory signature of severe COVID-19 specifically modulated throughout the course of the disease. Methods Luminex technology and enzyme-linked immunosorbent assay were used to assess plasma levels of platelet inflammatory markers in patients with severe acute respiratory syndrome coronavirus 2 infection on admission and for 14 days afterwards. Results In accordance with the observations of other teams, we evidence that the plasma levels of the platelet soluble (s)CD40L is significantly elevated in the early stages of the disease. Interestingly we observe that the plasma level of sCD40L decreases overtime while that of sCD62P increases significantly. Conclusions Our data suggest that there is a platelet signature of inflammatory response to SARS-COv-2 infection which varies overtime and could serve as monitoring biomarkers of patient inflammatory state. Clinical trial registration number: 2020-A01100-39; title: Human Ab Response & immunoMONItoring of COVID-19 Patients, registration date: 05/25/2020; URL of the registry: https://clinicaltrials.gov/ct2/history/NCT04373200?V_5=View .https://doi.org/10.1186/s12985-021-01680-3PlateletsInnate immunityCD40LInflammationSARS-CoV2 |
| spellingShingle | Hind Hamzeh-Cognasse Alexandre Mansour Florian Reizine Patrick Mismetti Isabelle Gouin-Thibault Fabrice Cognasse Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection Virology Journal Platelets Innate immunity CD40L Inflammation SARS-CoV2 |
| title | Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection |
| title_full | Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection |
| title_fullStr | Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection |
| title_full_unstemmed | Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection |
| title_short | Platelet-derived sCD40L: specific inflammatory marker for early-stage severe acute respiratory syndrome coronavirus 2 infection |
| title_sort | platelet derived scd40l specific inflammatory marker for early stage severe acute respiratory syndrome coronavirus 2 infection |
| topic | Platelets Innate immunity CD40L Inflammation SARS-CoV2 |
| url | https://doi.org/10.1186/s12985-021-01680-3 |
| work_keys_str_mv | AT hindhamzehcognasse plateletderivedscd40lspecificinflammatorymarkerforearlystagesevereacuterespiratorysyndromecoronavirus2infection AT alexandremansour plateletderivedscd40lspecificinflammatorymarkerforearlystagesevereacuterespiratorysyndromecoronavirus2infection AT florianreizine plateletderivedscd40lspecificinflammatorymarkerforearlystagesevereacuterespiratorysyndromecoronavirus2infection AT patrickmismetti plateletderivedscd40lspecificinflammatorymarkerforearlystagesevereacuterespiratorysyndromecoronavirus2infection AT isabellegouinthibault plateletderivedscd40lspecificinflammatorymarkerforearlystagesevereacuterespiratorysyndromecoronavirus2infection AT fabricecognasse plateletderivedscd40lspecificinflammatorymarkerforearlystagesevereacuterespiratorysyndromecoronavirus2infection |